Please Note: All times are Eastern. Our 60-minute webinars
begin at 1:00 pm Eastern / 12:00 noon Central / 11:00 am Mountain / 10:00 am
This presentation aims to put the SGLT-2 Inhibitor and GLP-1 Receptor Agonist Cardiovascular Outcomes Trials (CVOTs) into context. We will review study designs, patient populations, and outcomes in patients with established cardiovascular (CV) disease and in patients with risk factors.
This webinar is part of a series of educational activities presented by AADE in association with AstraZeneca-US Medical Affairs, CVMD Division. This webinar is educational in nature and contains no promotional or product information. CE credit is not available for this activity.
-- Understand key elements in how CVOTs were designed, including key differences in patient populations and treatment duration.
-- Understand post-hoc attempts to understand effects in patients with established disease and in patients with risk factors.
-- Describe key takeaways and how these results are impacting treatment guidelines and future directions of research.
James A. Ruggles, PhD
Executive Medical Director, CVMD
Curtis Triplitt, PharmD, CDE
Clinical Associate Professor, Medicine/Diabetes
University of Texas Health Science Center at San Antonio
Texas Diabetes Institute
This activity is designed for diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants, MDs, and other health care providers interested in staying up to date on current practices of care for their patients with diabetes and other related conditions.
This 60-minute online session includes a presentation followed by a question and answer period.
Test Your Computer
To ensure that your participation is successful, please test your system as
soon as possible so if you do have technical challenges, you will have time to
get them sorted out. Click here to test your computer.
While you can participate with a 56K dialup internet
connection, it is recommended that you have a high-speed broadband (or better)
internet connection. Please be sure you close as many open programs on your
system as possible.
Click here for operating system